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Abstract
Background: Switching or reclassifying medicines with established safety profiles from prescription to non-prescription
aims to increase timely consumer access to medicines, reduce under-treatment and enhance self-management. However,
risks include suboptimal therapy and adverse effects. With a long-standing government policy supporting switching or
reclassifying medicines from prescription to non-prescription, the United Kingdom is believed to lead the world in switch,
but evidence for this is inconclusive. Interest in switching medicines for certain long-term conditions has arisen in the
United Kingdom, United States, and Europe, but such switches have been contentious. The objective of this study was then
to provide a comprehensive comparison of progress in switch for medicines across six developed countries: the United
States; the United Kingdom; Australia; Japan; the Netherlands; and New Zealand.
Methods: A list of prescription-to-non-prescription medicine switches was systematically compiled. Three measures were
used to compare switch activity across the countries: ‘‘progressive’’ switches from 2003 to 2013 (indicating incremental
consumer benefit over current non-prescription medicines); ‘‘first-in-world’’ switches from 2003 to 2013; and switch date
comparisons for selected medicines.
Results: New Zealand was the most active in progressive switches from 2003 to 2013, with the United Kingdom and Japan
not far behind. The United States, Australia and the Netherlands showed the least activity in this period. Few medicines for
long-term conditions were switched, even in the United Kingdom and New Zealand where first-in-world switches were most
likely. Switch of certain medicines took considerably longer in some countries than others. For example, a consumer in the
United Kingdom could self-medicate with a non-sedating antihistamine 19 years earlier than a consumer in the United
States.
Conclusion: Proactivity in medicines switching, most notably in New Zealand and the United Kingdom, questions missed
opportunities to enhance consumers’ self-management in countries such as the United States.
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Introduction
In contrast to her British counterpart, an American woman can
now self-medicate for urinary incontinence. Conversely, without a
prescription, this American woman cannot access a statin for her
moderate cardiovascular risk, unlike in the United Kingdom (UK);
nor can she effectively treat her urinary tract infection, unless she
is visiting New Zealand (NZ). Such examples of variation in
switching (or reclassifying) medicines from prescription to non-
prescription availability have implications for consumer access and
healthcare. For example, switching cold medications in the 1970s
resulted in nearly two million fewer doctor consultations for colds
per year in the US [1], and an OTC switch of triptans was
estimated to save health funders J75 million in one year across six
European countries [2].
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In the UK, government policy has long encouraged self-care,
including through switching medicines [3]. Such a sustained
government interest in medicines switching is uncommon inter-
nationally, although occasionally governments have driven
switches to enable consumer access [4] or reduce health funding
costs [5,6].
In the early 2000s, stakeholder groups in the UK [7], and
Europe [8] identified medicines for long-term conditions and
antibiotics as potential switch candidates. While contentious
[9,10], interest in switches outside of the traditional minor ailment
arena is continuing. For example, the American College of
Obstetricians and Gynecologists recommended a switch of the oral
contraceptive to reduce unintended pregnancy [11], and others
have proposed this action given the cancer-prevention benefits of
combined oral contraceptives [12]. Furthermore, in 2012, the
United States (US) Food and Drug Administration (FDA)
proposed that switching medicines may address the under-
treatment of some chronic conditions [13]. In light of shortages
of primary care physicians [14] and escalating healthcare costs in
the US [15], switching medicines may indeed reduce some
barriers to access.
Concerns about switching include inaccurate diagnosis [16],
suboptimal therapy [17], and inappropriate use, including misuse
[18]. On the global stage, however, switching is taking place,
without reversals, and with support from some governments.
To have an informed perspective on, and be engaged in, change
involving medicines switches, the health professionals and policy
makers require understanding of what is happening across health
systems under mounting pressure to provide better value for
money. Switches in one country may provide ideas for widening
consumer access to medicines in another country, and an
opportunity to learn from another country’s experience.
Apart from isolated comparisons of individual medicines [4,5],
international progress in switching medicines, including those for
long-term conditions, has not been systematically documented.
The US Government Accountability Office (GAO) [19] and
Gilbert and colleagues [20] found that countries varied in the
number of active ingredients available without prescription, but
provided no indication of the nature of the variation, or switch
activity over time. Although the UK is believed to lead the world
in switch [3], neither of these studies confirmed this belief, perhaps
reflecting methodological deficiencies [21]. Thus, this paper aims
to assess variation in switching medicines from prescription to non-
prescription among selected developed countries.
Methods
We identified similarly-developed countries ranking highly (45
or above) on education, health, and socioeconomic development
and functioning, in the United Nations Human Development
Index [22]. Countries were then purposively sampled to represent
diversity in medicines schedules, geographical location, popula-
tion, health system funding, and culture. The countries compared
were the US, UK, Japan, the Netherlands, Australia, and NZ.
Inclusion of Australia and NZ allowed comparisons between two
countries with similar histories, societies, locations, welfare
systems, and medicines classifications. Uniquely, these two
countries have attempted to harmonize their scheduling since
the mid-1990s [21].
The US has a single non-prescription category which does not
restrict the medicines to pharmacies or require a pharmacist to be
present (open availability) [23]. The UK has two non-prescription
classifications: pharmacy-only and general sales (open availability)
[23]. Other countries have three non-prescription classifications.
NZ and Australia have pharmacist-only, pharmacy-only, and
general sales classifications [21]. The Netherlands has pharmacy-
only, drugstore and pharmacy, and general sales classifications
[23]. Japan restricts non-prescription medicine sales to pharma-
cists only (category one medicines), or supply by a registered
person or pharmacist (category two and category three medicines)
[23]. The trained registered person may supply category two or
three medicines without a pharmacist present. ‘‘Quasi-drugs’’ such
as vitamins and gargles can be sold from stores that do not have a
pharmacist or registered person on staff.
The lead author accessed documents from the US, UK, NZ,
and Australia that identified prescription-to-non-prescription
switches and their dates. US data were derived from the
Consumer Healthcare Products Association website [24] and
validated against news articles in academic journals. UK sources
included regulator consultation documents on switches, Pharma-
ceutical Journal news articles, and industry and pharmaceutical
society documents [25,26]. For Japan, NK and NG ascertained
dates of switches from official government websites [27] and other
documents [28,29] as required. For the Netherlands, the
pharmaceutical professional organization (Koninklijke Neder-
landse Maatschappij ter bevordering der Pharmacie; KNMP)
and industry organization (Neprofarm) provided information in
the absence of local records in English. NZ and Australian source
documents included meeting records for scheduling committees
(2000–2013 for Australia and 1990–2013 for NZ), an Australian
PhD thesis [30], and the Australian Self-Medication Industry for
dates otherwise unavailable.
In this paper, we have used the term ‘switch’ to mean a move
from prescription to non-prescription availability whether over-
the-counter or provided behind-the-counter (as with pharmacist-
only supply in Australia). Switches were analysed on three
measures. The first measure compared prescription-to-non-
prescription switches from 2003 to 2013, with a specially
developed descriptor, ‘‘progressive’’ switches (also known as
‘‘innovative’’ switches). This measure adapted the methodology
used for FDA priority reviews for registering new chemical entities,
and has been described elsewhere [21]. A progressive switch for an
individual country was one providing incremental consumer
benefit, either:
(1) safe and effective therapy where no satisfactory non-
prescription therapy existed in that country; or
(2) a clinically-significant improvement compared to current
non-prescription therapies in that country.
Authors NG, FK, LB, and LE agreed whether or not the
medicine met the progressive switch criteria, with input from NK
for Japan. Use of these criteria for Australia and NZ has been
outlined elsewhere [21]. Table S1 in Supporting Information
illustrates the use of these criteria for the other countries. The
second measure determined whether a medicine switch was, to the
best of our knowledge, the first switch for that type of drug in the
developed world (‘‘first-in-world’’) from 2003 to 2013. The final
measure compared switch dates for pharmacological classes of
medicines, or selected medicines in the case of non-steroidal anti-
inflammatory agents (to highlight variation between countries) or
for medicines unique to a class (e.g. orlistat). These comprised
medicines that were progressive switches in the selected countries
from 2003 to 2013, along with five switches that occurred across
most or all countries before 2003 (ibuprofen, H2-antagonists,
nicotine replacement therapy, dermal hydrocortisone 1%, and
mast cell stabilizers), and an early switch limited to Australia and
the US (short-acting beta-agonists).
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Results
Prescription to non-prescription switch activity varied between
and within countries over time (Figure 1, Table 1). NZ, the UK,
and Japan were the most active during the study period, with 11–
16 progressive switches each. In contrast, the US, Netherlands,
and Australia had around half of the switches experienced by
Japan and the UK. Variation over time in Table 1 includes a
recent slowdown in progressive switches in the UK, and inactive
periods in the US and Australia. Japan was particularly active in
switches in 2007–2008. Much of NZ’s recent activity has been
driven by vaccine switches, unlike other countries.
The UK and NZ had the most first-in-world switches during
2003–2013 (Table 2). In both countries, these switches included
departures from the self-diagnosable minor ailments traditionally
considered the domain of non-prescription medicines, e.g.
simvastatin, tamsulosin, and topical calcipotriol for long-term
use. Most of these medicines have not been subsequently switched
in any of the other selected countries.
The final measure, comparing switch dates for selected
medicines (Table 3), shows considerable delays in some switches,
particularly in the US and Japan compared with others. Japan
appears less progressive than its recent activity (Figure 1) would
suggest.
Some switches exhibit a ‘‘ripple effect’’, with widening access in
one country which is then followed elsewhere e.g. ibuprofen and
H2-antagonists (Table 3). Large delays between countries some-
times occurred. US consumers needed a prescription for non-
sedating antihistamines, and for nasal corticosteroids for 19 years
longer than did UK consumers. Vaginal antifungal switches were
considerably delayed in the Netherlands and Japan compared with
the US.
While typically the UK had removed the prescription restriction
of many medicines earlier than the other countries, naproxen was
exceptionally delayed compared with most other countries. The
US switched some medicines relatively early, e.g. ibuprofen,
vaginal antifungals, and proton pump inhibitors. The early (1982)
US switch of the asthma reliever, orciprenaline (metaproterenol),
was quickly reversed, unlike the Australian switch of the asthma
reliever, salbutamol (albuterol) which still remains switched. Japan
differed most from the other countries, in switching medicines that
are not marketed in the other countries examined (see Table S1 in
Supporting Information), and in different strengths, doses or
indications to other countries, e.g. tranexamic acid. Australia and
NZ switched many of the same medicines until the mid-2000s then
diverged. All three measures of switch showed NZ to be more
active than Australia currently, but, unlike Australia, NZ has not
switched an inhaled asthma reliever.
Discussion
While the UK has broken new ground with switches, the effect
of government support for switch appears to be waning. NZ was
the most progressive in switch of the countries studied, across all
measures used. Consumers in the more restrictive US and the
Netherlands have continued to need to access doctors for a
number of common medicines that have been switched in the UK
and NZ. The number of progressive switches differed three-fold
across the six selected countries in the 11 years to 2013.
This research demonstrated considerable differences between
countries in switching certain identical medicines or classes of
medicines. The difference in access may bring advantages and
disadvantages to medical care, consumers and society in the
different health systems. For example, Americans required a
prescription for non-sedating antihistamines for considerably
longer than all other countries, despite safety benefits over
sedating antihistamines [33], which have long been non-prescrip-
tion. Sedating antihistamines have been associated with work-
place, car, and aviation accidents [34]. Dutch women with vaginal
candidiasis required a prescription for vaginal antifungals until
2011, 21 years later than in the US and NZ, with potentially
unnecessary doctor workload, higher costs for the health funder,
and prolonged discomfort and inconvenience for women. Retain-
ing vaginal antifungals as prescription medicines might have
minimized inappropriate use (including unnecessary consumer
costs) and encouraged earlier diagnosis of serious conditions.
However, American [35] and Finnish [36] doctors supported
continued non-prescription availability of vaginal antifungals,
despite some doctors reporting consumer self-care deficiencies
with vaginal antifungals.
The early (1983) UK switch of the non-sedating antihistamine
terfenadine was later reversed following evidence of cardiac effects
[3]. While this example suggests that delaying switch might
sometimes be beneficial, new switches occurring in the selected
countries over the last 10 years have not been reversed on account
of safety reasons. Considering the variation in switching medicines
with a benign safety profile and limited risk of masking serious
conditions, e.g. non-sedating antihistamines and mast cell stabi-
lizers, our data suggest that factors that are not safety-related may
delay switch.
Other researchers have reported international variation in
medicines availability [19,20], but by providing only a numerical
Figure 1. Progressive medicine switches 2003–2013.
doi:10.1371/journal.pone.0107726.g001
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comparison and including ‘‘me-toos’’ and obsolete drugs [21], the
implications for consumer access and medical management are
unclear. Our research is the first to show the nature of the
international variation through assessing multiple countries over
time and using multiple tools.
Opinion seems divided on whether a pharmacy-only or
pharmacist-only category affects non-prescription availability
[19,20]. We found that the US, with a single open non-
prescription category, appeared less active in switch than the
UK, and NZ, which have pharmacist-only and/or pharmacy-only
classes. Low switch activity in the Netherlands (despite a
pharmacy-only class) and the differences between NZ and
Australia (despite similar schedules and attempted harmonization
of scheduling) suggest other factors are also involved. In NZ some
switched medicines, e.g. vaccines and trimethoprim, can only be
supplied under strict criteria and through specially trained
pharmacists [21], possibly enabling switches.
We found that few long-term medicines were switched, despite
interest in such switches in multiple jurisdictions [7,8,13]. The UK
has been most active in this field, but most medicines for long-term
conditions identified by the UK working party [7] remain
prescription-only. Despite statin switch attempts in the US [17]
and NZ [21], only the UK had switched a statin. Some may view
the reluctance to switch statins positively, given concerns expressed
in the UK about efficacy, compliance, and unknown hazards [10].
Although suggested as suitable for non-prescription supply [12],
Table 1. Progressive switches, 2003–2013.
Year Australia NZ US UK Japan Netherlands
2003 EHC; fluconazole Omeprazole;
loratadinea
Omeprazole
2004 Orlistat Fluconazole; orlistat Simvastatin; hyoscine
(transdermal)
Minoxidil (scalp)a
2005 Pantoprazole Alclometasone (dermal) Chloramphenicol (ocular) EHC
2006 Sumatriptan; oseltamivir EHC Sumatriptan; amorolfine
(nail)
Triamcinolone (mouth)










Orlistat; tamsulosin Loxoprofena Ipratropium
(nasal); orlistat



















Note: All medicines are oral preparations, unless otherwise stated. ETEC = enterotoxigenic Escherichia coli; EHC = emergency hormonal contraception.
a. Extended indication or increased strength rather than new switch.
b. In combination with ascorbic acid, L- cysteine, pantothenic acid, and pyridoxine, for chloasma.
c. For hypertriglyceridaemia.
doi:10.1371/journal.pone.0107726.t001
Table 2. First-in-world medicine switches, 2003–2013.
UK NZ Australia Netherlands US Japan
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Table 3. Comparison of timing of selected medicine switches across countries up to and including 2013.
Medicine or class of medicines UK NZ Aust-ralia Nether-lands US Japan
Inhaled short-acting beta agonist X X 1976a X Xb X
Urinary bladder spasm treatment (flavoxate) X ,1990c ,1990c X X 2007
Non-sedating antihistamine 1983d ,1990 #1992 #1995 2002 1990
Ibuprofen 1983 1985 1989 ,1987 1984 1985
Naproxen 2008 #1990 1983a 1996 1994 X
Dermal hydrocortisone 1% 1987 1990 ,1997 X 1991 Xe
Nicotine replacement (any form) 1991 ,1990 1988a ,1992 1996 2001
Vaginal azole antifungal 1992 1990 1994 2011 1990 2007
Dermal nucleoside analogue (e.g. aciclovir) 1993 1990 1996 #2000 X 2007
Nasal corticosteroid 1994 1996 1999 X 2013 2010
H2-antagonist 1994 1993 1995 #1996 1995 1997
Steroid for local oral use 1994 1991 1996 X X 2006
Mast cell stabilizer (any form) 1994 1991 ,1990 #1995 1997 1996
Azole antifungal (oral, single dose) 1995 2004 2003 X X X
Mebeverine 1997 X X X X X
Domperidone 1998 X X ,1991 X X
Dermal moderate potency corticosteroid 2001 2005 2000 X X X
Orlistat 2009 2004 2004 2009 2007 X
Proton pump inhibitor 2003 2008 2005 2008 2003 X
Emergency hormonal contraceptive 2001 2001 2003 2005 2006 X
Statin 2004 X X X X X
Ocular chloramphenicol 2005 2009f 2010f X Xf Xf
Triptan 2006 2006 X X X X
Neuraminidase inhibitor (oseltamivir) X 2006 X X X X
Chlamydia treatment (azithromycin) 2008 X X X X X
Alpha-1 blocker (tamsulosin) 2009 X X X X X
Oral antiviral for herpes labialis X 2009 2011 X X X
Tranexamic acid 2010 X Xg X X 2007h
Dermal calcipotriol X 2010 X X X X
Cholera and travellers’ diarrhoea vaccine X 2011 X X X X
Influenza vaccination X 2012 X X X X
Trimethoprim X 2012 X X X X
Transdermal oxybutynin X Xi X X 2013 X
Meningococcal vaccine X 2013 X X X X
Tetanus-diphtheria-pertussis vaccine X 2013 X X X X
Herpes zoster vaccine X 2013 X X X X
X = not switched.
a. In early Australian switches timing differed between the States and Territories, the earliest switch date is shown.
b. Orciprenaline (metaproterenol), a non-selective beta-agonist was switched in the US in 1982, but reversed in 1983 [31].
c. Flavoxate is non-prescription in both Australia and NZ, but marketed in neither.
d. The non-sedating antihistamine switched in the UK in 1983 was terfenadine, which later reverted to prescription medicine following QT prolongation concerns [3].
e. Hydrocortisone 1% with oxytetracycline (but not alone) has long been available without prescription in Japan.
f. Other antibacterial eye preparations have long been available without prescription in these jurisdictions, e.g. sulfacetamide in NZ and Australia, polymyxin and
bacitracin in the US, and sulfamethoxazole in Japan.
g. Tranexamic acid was switched in Australia in 2000 but never marketed as a non-prescription medicine and reverted to prescription in 2007 under Trans-Tasman
Harmonization.
h. Tranexamic acid in Japan was switched at a lower dose, in combination with other ingredients, and for a different indication to the UK (chloasma not menorrhagia)
[32].
i. Oral oxybutynin was previously available without prescription in NZ.
Note: Medicines are oral unless otherwise specified. All vaccines are injected except for the cholera and travellers’ diarrhoea vaccine which is oral.
doi:10.1371/journal.pone.0107726.t003
Switching Medicines to Non-Prescription: Comparing Six Countries
PLOS ONE | www.plosone.org 5 September 2014 | Volume 9 | Issue 9 | e107726
oral contraceptives have not switched in any of the six countries.
Our data do not show why such switches have not occurred.
In some countries, mechanisms other than switch may increase
consumer access to prescription medicines, as with vaccines in the
US [37], and widening prescribing rights to non-physician
practitioners [3], possibly circumventing some of the need for
switch.
A full investigation of reasons for the variation across countries
and over time is warranted, and a subject of our ongoing research.
Evaluating the appropriateness, and risks and benefits of each
switch would be difficult since little post-switch research is
conducted. Dr June Raine from the UK’s Medicines and
Healthcare products Regulatory Agency (MHRA) believed that
for the UK’s switches ‘‘…the benefits of wider access to medicines
overwhelmingly outweigh the risks’’ [38]. Indeed, none of the new
switches from the last decade in the selected countries has been
reversed, providing confidence in the process. However, sponta-
neous adverse event reporting has deficiencies [39], and will not
identify under-treatment, over-treatment, and delayed diagnosis.
This study used information-rich multi-dimensional means to
highlight differences in switch activity between six countries. It
moves away from reliance on industry tables [19,20], and a simple
quantitative comparison irrespective of consumer advantage. We
focused on the move from prescription-only to non-prescription
availability, recognizing the strong potential impact on access and
doctor involvement with this change.
We have sought to validate our findings by triangulating switch
data with multiple documents or consulting with knowledgeable
persons in each country. Official meeting records (as used in NZ
and Australia) were not triangulated with other sources. Finding
appropriate data and assessing whether or not a switch was
progressive were difficult when little information was available in
English (e.g. Japan and the Netherlands). Switch dates used may
be committee decision dates, official gazettal dates or product
launch dates. However, overall findings would not have differed
with occasional changes in how the progressive criteria were
applied or the slight variation in dates used. Furthermore,
comparing all switches would have been less informative than
comparing progressive switches because of ‘‘me-too’’ switches in
some countries. The finding of diversity in switch may reflect the
countries chosen. Had selected countries been more similar,
switches might have been more homogeneous, but the variation
between NZ and Australia suggests that even similar countries
may differ in switch activity.
Implications
Consumer access to medicines through switch differs across
countries with similarly educated consumers. This difference
suggests that the health system in some countries could be
unnecessarily burdened by managing conditions that may
reasonably be self-managed or pharmacist-managed instead.
Providing vaccinations through pharmacists, as in NZ, may
reduce some barriers to access, and therefore have public health
benefits. Perhaps pharmacy or pharmacist-supply availability, as
occurs in the more active countries, may help widen consumer
access to medicines in the US.
Our findings raise questions as to why countries vary in
switching medicines. They also invite investigation into consumer
outcomes of the differences in access. These outcomes pertain to
realized access versus potential access [40], cost, and the safety and
quality of healthcare. Widespread problems following the last 10
years of switches have not become evident, nor have recent
switches been reversed, but post-marketing surveillance studies of
switched medicines to confirm their safety are rare. Outcome data,
including multi-country comparisons of outcomes from differences
in switch, could be used to explore realized benefits and risks of the
differences seen and help to inform further switches.
Conclusion
Our multi-dimensional study provides benchmarking of switch,
and therefore consumer access to medicines, in the six selected
countries, and allows other countries to compare their activity with
our findings. We found variation between countries in switch
activity, and variation in activity over time within some countries.
Progressive in this area, the UK and NZ appear willing to approve
ground-breaking switches, although the UK may be slowing down.
Other countries require of their consumers a prescription for some
medicines switched elsewhere, indicating scope for the Nether-
lands, Australia, and the US to widen access to medicines through
switch.
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